Yoshio Kiyohara - Concepedia

Author

Yoshio Kiyohara

Shizuoka Cancer Center ORCID

Also Known As

K Yoshio, Kiyohara, Y., Takamichi Ito, Y Kiyohara, Y. Kiyohara, YOSHIO KIYOHARA, Yoshio KIYOHARA, Yoshio Kiyohara

193

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Shizuoka Cancer Center Shinshu University Niigata Cancer Center Hospital Kyushu University Saitama Medical University

About

Yoshio Kiyohara is an author at Shizuoka Cancer Center specializing in medicine, oncology, and dermatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	25	1.5K
2	Health Sciences	3	3	81
3	Engineering	2	2	103
4	Cell Biology	2	2	155
5	Allergy	1	1	20

Yoshio Kiyohara

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors Kuniaki Ohara, Yasuhiro Fujisawa, Koji Yoshino, Journal of Dermatological Science Surgical OncologyTnm Staging SystemTumoral PathologyMedicineSurgical Pathology	2016	148
Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Cancer Science Cytokine BiomarkersImmunologyImmunoeditingImmunotherapeuticsImmunotherapy	2017	124
Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial Chie Oshita, Masako Takikawa, Akiko Kume, Oncology Reports ImmunologyDendritic Cell-based VaccinationImmunodominanceImmunoeditingImmunotherapeutics	2012	102
Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients Takeshi Nagashima, Ken Yamaguchi, Kenichi Urakami, Cancer Science EngineeringPathologyCancer RegistrationCancer PatientsCancer Biology	2019	89
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041) Naoya Yamazaki, Tatsuya Takenouchi, Manabu Fujimoto, Cancer Chemotherapy and Pharmacology Phase 1BAnti-pd-1 Monoclonal AntibodyMedicineMelanomaImmunology	2017	86
Usefulness of docetaxel as first‐line chemotherapy for metastatic extramammary Paget's disease Koji Yoshino, Yasuhiro Fujisawa, Yoshio Kiyohara, The Journal of Dermatology	2015	79
The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease: Multi-center, retrospective study of 151 patients Yasuhiro Fujisawa, Koji Yoshino, Yoshio Kiyohara, Journal of Dermatological Science Retrospective StudySurgical OncologySurgical PathologyPathologyInvasive Extramammary Paget	2015	74
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study Kenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, European Journal of Cancer	2018	72
Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Ayako Suzuki, Akira Iizuka, Masaru Komiyama, PubMed	2010	71

Page 1